HomeORX • STO
Orexo AB
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (SEK) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 146.20M | 4.95% |
Operating expense | 124.70M | -7.36% |
Net income | -15.90M | -78.65% |
Net profit margin | -10.88 | -70.27% |
Earnings per share | -0.46 | -76.92% |
EBITDA | 11.90M | -0.83% |
Effective tax rate | 17.19% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (SEK) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 119.10M | -39.85% |
Total assets | 529.00M | -36.26% |
Total liabilities | 690.30M | -10.18% |
Total equity | -161.30M | — |
Shares outstanding | 34.51M | — |
Price to book | -4.31 | — |
Return on assets | 0.36% | — |
Return on capital | 0.59% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (SEK) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -15.90M | -78.65% |
Cash from operations | 32.90M | 274.07% |
Cash from investing | -19.20M | -1,500.00% |
Cash from financing | -7.00M | -116.17% |
Net change in cash | -4.10M | -115.19% |
Free cash flow | 56.31M | 307.89% |
Previous close
kr20.15
Day range
kr19.10 - kr20.15
Year range
kr9.18 - kr24.00
Market cap
697.68M SEK
Avg Volume
23.48K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
About
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
Founded
1995
Website
Employees
110
